Združene države Amerike - angleščina - NLM (National Library of Medicine)

proficient rx lp - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets, usp are indicated in: sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

pacific pharma, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

redpharm drug - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

bryant ranch prepack - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets are indicated in:  - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.  sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

allergan, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - carafate®  (sucralfate) is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. carafate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

allergan, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - carafate (sucralfate) oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. carafate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

ax pharmaceutical corp - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lansoprazole, quantity: 30 mg - tablet, orally disintegrating - excipient ingredients: crospovidone; magnesium carbonate hydrate; aspartame; macrogol 6000; sodium bicarbonate; iron oxide yellow; sodium starch glycollate type a; citric acid monohydrate; hyprolose; magnesium stearate; mannitol; sodium lauryl sulfate; purified talc; iron oxide red; microcrystalline cellulose; sodium hydroxide; triethyl citrate; polysorbate 80; methacrylic acid - ethyl acrylate copolymer (1:1); sucrose; maize starch; flavour - adults,1.healing and long-term management of reflux oesophagitis. ,2.healing and long-term management for patients with duodenal ulcer. ,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists. ,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials). ,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. ,paediatric patients 6 to 17 years of age. ,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. ,2.healing of erosive oesophagitis.